Eurand N.V. News

Eurand reports Phase II/III study data for ZENPEP in chronic pancreatitis patients with exocrine pancreatic insufficiency M2Europharma on Friday, 13 November 2009 at 19:10 GMT 13 November 2009 - Netherlands-based specialty pharmaceutical company Eurand N.V. reported on Friday findings from a Phase II/III study demonstrating that ZENPEP ...

Greetings ladies and gentlemen and welcome to the Eurand third quarter 2009 financial results conference call.

The shares offered include the 1,275,000 shares underlying the over-allotment option that the underwriters exercised.

Drug developer Eurand NV said Thursday it and certain shareholders plan to publicly offer a combined 8.5 million shares of common stock.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Eurand N.V. received FDA approval for its NDA for Zenpep Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis or other conditions.

Stock futures were pointing to a higher open as Wall Street waits on the release of consumer sentiment numbers due out later this morning.

Eurand N.V., a specialty pharmaceutical company, today announced FDA approval of its New Drug Application for ZENPEP Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis or other conditions.

Main Category: Pharma Industry / Biotech Industry Also Included In: Pharmacy / Pharmacist Article Date: 21 Jul 2009 Eurand N.V. , a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the Dutch Medicines Evaluation Board informed ...

Main Category: GastroIntestinal / Gastroenterology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 23 Jun 2009 Eurand N.V. , a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the U.S. Food and Drug ...

Eurand N.V., a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on proprietary pharmaceutical technologies, has announced that the FDA has advised the company that it has extended the June 2009 user fee goal date for the New Drug Application for ZENPEP by three months.

Eurand N.V. , a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that Gearoid Faherty, Chairman and Chief Executive Officer, is scheduled to present at the following conference: Event: UBS Global Specialty Pharmaceuticals ...

Co-developed by Eurand and GSK, Lamictal ODT uses Eurand's AdvaTab orally disintegrating tablet and Microcaps taste-masking technologies to provide Lamictal in a pleasant-tasting tablet that disintegrates on the tongue and that may be taken with or without liquid.